Giampaolo Bianchini, Head of Clinical Translational and Immunotherapy Research at Ospedale San Raffaele, shared a post on X about a paper he co-authored with colleagues published in Annals of Oncology:
“QoL improvement is an important goal in advanced cancer.
In SERENA 6, early shift to camizestrant demonstrated consistent benefit in delayed time to deterioration of PRO cancer symptoms (pain, fatigue, dyspnoea) and functioning.”
Title: Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
Authors: E.L. Mayer, F.-C. Bidard, Y.H. Park, W. Janni, C. Ma, M. Cristofanilli, H. Iwata, G. Bianchini, K. Kalinsky, S. Chia, A. Brufsky, P.A. Fasching, Z. Nowecki, S.-C. Chen, J. Pascual, L. Moreau, M. Ruiz-Borrego, A. Shai, N. Karadurmus, J.H. Sohn, Y. Zhu, I. Leddin, M.S. Miralles, C.H. Bartlett, and N. Turner
You can read the Full Article in Annals of Oncology.
Follow the latest ESMO 2025 news on OncoDaily.
